1. Executive Overview {#executive-overview}

Dephy is a robotics and wearable-technology company best known publicly for the Dephy Sidekick, a smart powered insole system designed to reduce the physical effort of walking. The Sidekick's core engineering credentials are notable: a 0.001-second sensor response time (1,000 Hz update rate), ISO 13482 safety-standard compliance, adaptive gait learning in as few as 20 strides, and a real-world range of 3–5 miles per charge — all in a package weighing 1.4 kg per side including the battery. These specifications position Dephy in the emerging consumer and wellness segment of wearable robotics, a space that independent coverage by Exoskeleton Report and Fox News confirms is attracting genuine mainstream attention.

The company's public-facing profile remains relatively lean: founding date, country of incorporation, funding history, and team size are not disclosed on the company's own site. What is clear is that Dephy has moved a technically sophisticated product — one with roots in exoskeleton research — into a form factor designed for everyday use without a clinician or a smartphone app as an intermediary. That is a meaningful design philosophy statement, and it is supported by the product's documented feature set.

Not yet disclosed: broader corporate background (leadership team, investor backing, facility locations). Dephy is invited to claim or correct any such details through the contact channels listed on dephy.com.

2. The Company Story {#the-company-story}

Dephy's founding date and country of headquarters are not disclosed in the publicly available data on dephy.com. What the company's own site and third-party coverage do establish is that Dephy sits at the intersection of exoskeleton research and consumer wellness technology — a positioning confirmed by Exoskeleton Report, an industry-specialist outlet, which tracks Dephy as a notable player in the powered-exoskeleton space.

The trajectory implied by the Sidekick product itself is instructive. Powered ankle-assist exoskeletons have historically been large, expensive, lab-bound systems. The Dephy Sidekick — attaching at the heel and shin, learning a user's gait in 20 strides, requiring no app, and retailing as a wellness product rather than a regulated medical device — represents a deliberate commercialization step: taking actuator and adaptive-control technology developed in research contexts and packaging it for everyday consumers. This mirrors a broader industry pattern that Fox News described in a February 2026 feature on wearable robotics moving "from research labs to everyday life," in which Dephy's work was contextually relevant.

A Fox News article from October 2025 covering Nike's Project Amplify — motor-powered shoes — further situates Dephy in a competitive moment when major consumer brands are entering motor-assisted footwear, lending urgency to Dephy's positioning as a specialist with deeper technical roots in the exoskeleton field.

Not yet disclosed: specific founding year, named founders, funding rounds, or key partnership milestones. Dephy is invited to share that history for inclusion in future updates.

3. Product Portfolio {#product-portfolio}

Products & versions

C30

DELIVERY

DINERBOT T9 Pro

HOSPITALITY

KLEENBOT C30

CLEANING

BUTLERBOT W3

DELIVERY

DINERBOT T9

DELIVERY

T10

HOSPITALITY$15,000

Dephy's publicly documented product lineup currently consists of a single commercial offering: the Dephy Sidekick. While a one-product portfolio may appear narrow, the Sidekick itself is technically layered. It combines a brushless motor, an onboard sensor array operating at 1,000 Hz, and adaptive control software — components that individually represent non-trivial engineering investment. The product attaches to compatible footwear at the heel and shin, uses a calf strap and quick-connect system for secure fit, and delivers propulsive assist during the push-off phase of the gait cycle across three selectable power levels.

The Sidekick's classification as a wellness product rather than a medical device is a deliberate commercial positioning choice. It lowers the regulatory barrier to sale and broadens the addressable consumer market to anyone seeking reduced walking effort — not only patients in clinical pathways. The removable battery supports portable charging and practical daily use. Whether Dephy maintains additional products in development, in clinical evaluation, or under OEM/research licensing agreements is not yet disclosed on the company's public site. Dephy is invited to claim or correct the completeness of this portfolio listing.

4. Technology Stack {#technology-stack}

The Dephy Sidekick's published specifications permit several grounded observations about the underlying technology stack, supplemented where appropriate by labeled inference.

Actuation: The system uses a brushless motor to deliver push-off assist. Brushless DC motors are standard in precision robotics applications due to their efficiency, longevity, and controllability — consistent with the sub-millisecond response requirement the Sidekick meets.

Sensing and Control: The 0.001-second response time and 1,000 Hz update rate indicate that onboard sensors — almost certainly inertial measurement units (IMUs) and/or force/pressure sensors in the insole — are sampled and acted upon in real time. Our read: this is a closed-loop adaptive controller, not a simple timer-triggered assist; the "20 strides to learn gait" feature strongly implies an onboard machine learning or pattern-matching algorithm that personalizes assist timing and magnitude without cloud connectivity (no app is required).

Power System: A removable battery delivers 3–5 miles of real-world range at a total system weight of 1.4 kg per side including the battery. Our read: this suggests a compact lithium-based cell optimized for energy density at low weight, with power electronics sized to the brushless motor's peak draw during push-off bursts.

Safety: ISO 13482 compliance — the international safety standard for personal-care robots — indicates the system has undergone formal risk assessment covering mechanical, electrical, and human-interaction hazards. This is a meaningful certification for a wearable actuated device and not a trivial checkbox.

Software / Interface: The absence of a required companion app is itself an architectural decision. Our read: control logic and gait adaptation run entirely on embedded hardware, which reduces latency, eliminates smartphone dependency, and lowers user-friction — all appropriate for a consumer wellness product targeting non-technical users.

Limited public technical detail exists beyond the above specifications; deeper stack information (processor architecture, sensor vendor, firmware update mechanism) is not disclosed on the company's site.

5. Research, Papers, Authors, Labs {#research-papers}

Dephy does not appear to be an active publisher of peer-reviewed academic research based on the publicly available information on dephy.com. This is consistent with the profile of a commercial wearable-robotics firm focused on product development and market deployment rather than academic dissemination. Exoskeleton Report tracks Dephy as a company operating in a field with strong academic roots, but no specific papers, authors, or laboratory affiliations are attributed to Dephy in the data available for this report.

Not yet disclosed: any academic collaborations, sponsored research programs, or white papers. Dephy is invited to claim or correct this characterization if research activity exists.

6. Media Evidence {#media-evidence}

Third-party press coverage of Dephy includes a dedicated profile on Exoskeleton Report (exoskeletonreport.com), the leading specialist outlet covering the powered-exoskeleton and wearable-robotics industry — representing meaningful domain-credible validation. Fox News featured wearable robotics technology in a February 2026 article describing the broader shift of such systems from research labs to everyday life, a context in which Dephy's Sidekick is directly relevant. A further Fox News piece from October 2025 covered Nike's Project Amplify motor-powered shoes, situating the consumer powered-footwear category — where Dephy competes — as a topic of mainstream media interest. Taken together, these three placements indicate that Dephy and its product category have cleared the threshold of general-audience media relevance, not merely specialist trade coverage.

7. Commercial Reality {#commercial-reality}

Revenue, unit sales volume, customer count, and return-on-investment data for Dephy are not disclosed on the company's public site or in the third-party sources available for this report. These figures should be treated as Not disclosed.

Pricing, distribution channels (direct-to-consumer, retail partners, enterprise/employer wellness programs), and geographic markets served are similarly not detailed in available public data.

Dephy is invited to share commercial metrics, customer testimonials, or deployment data for inclusion in future updates to this report. Such disclosures would materially strengthen the evidence base for prospective buyers, partners, and investors evaluating the company.

8. Markets and Use Cases {#markets-use-cases}

The Dephy Sidekick's documented design parameters define a clear, if broad, target market. The product is explicitly positioned as a wellness device for people who want easier walking — not a medical device for diagnosed patients, and not an industrial exoskeleton for occupational injury prevention. This places it at the consumer end of the wearable-robotics spectrum.

Consumer Wellness and Active Aging: The primary use case implied by the product description is reducing walking effort for healthy adults who experience fatigue, whether from age, fitness level, or occupational demand. The 3–5 mile range and lightweight form factor suggest design optimization for daily community ambulation rather than sport or heavy industry.

Walking Endurance and Comfort: The push-off assist mechanism targets the gait phase that is most metabolically costly, meaning users engaged in extended walking — commuters, travelers, retail or service workers on their feet all day, older adults maintaining independence — are plausible beneficiaries.

Adjacent Market Potential: The ISO 13482 compliance and the sophistication of the adaptive control system (1,000 Hz, gait learning) suggest technical headroom that could support adjacent applications — clinical rehabilitation, occupational wellness programs, or research licensing — though none of these are explicitly claimed by Dephy in available public materials. Our read: the wellness-product classification is a deliberate entry point, and the technology is overbuilt for purely casual use, which may signal broader ambitions.

Industry tags and explicit use-case classifications are not attached to the Sidekick in Dephy's public product data; the above derives from the product description and feature set.

9. Competitive Landscape {#competitive-landscape}

The consumer and wellness wearable-robotics category that the Dephy Sidekick occupies is nascent but rapidly filling. The October 2025 Fox News coverage of Nike's Project Amplify motor-powered shoes illustrates that large consumer-footwear incumbents with substantial brand, distribution, and manufacturing scale are now moving into motor-assisted footwear — a meaningful structural development for specialist companies in this space. Meanwhile, the broader exoskeleton market includes established players addressing medical rehabilitation, occupational safety, and military augmentation, some of whom may extend into consumer wellness as the technology matures and costs fall.

Dephy's differentiation, as evidenced by its published specifications, rests on technical depth: ISO 13482 certification, a 1,000 Hz adaptive control loop, and app-free gait learning in 20 strides are not trivial engineering achievements and represent a meaningful capability moat relative to simpler passive or semi-passive assistive footwear products. Whether that moat is durable against well-resourced consumer-electronics or footwear entrants is a key strategic question. The module above provides current peer-company context.

10. Country Advantage / Geopolitical {#geopolitical}

Section not material for this company.

11. Hype vs Real vs Ugly {#hype-real-ugly}

What is verifiable from published specifications (grounded): The Dephy Sidekick's core performance parameters — 0.001-second response time, 1,000 Hz update rate, 20-stride gait learning, 3–5 mile range, 1.4 kg per side, three power levels, ISO 13482 compliance — are published by Dephy on its own site. These are company claims; independent laboratory verification of these figures in published third-party tests is not available in the data for this report.

What is a reasonable inference (labeled): Our read: the ISO 13482 certification, if accurate, implies meaningful third-party safety validation, since that standard requires documented risk assessment processes. This is the strongest form of external substantiation present in the public data.

What is a company claim requiring further evidence: The description that the Sidekick "reduces effort" during walking is a functional claim. Quantified metabolic reduction data (e.g., percentage decrease in oxygen consumption) would be the standard scientific measure of such a claim for a powered ankle-assist device; no such figures are disclosed in available public materials.

What is a gap, not a confirmed negative: Not yet disclosed: independent clinical or biomechanical trial data, user-outcome studies, or third-party product reviews quantifying performance. Dephy is invited to share or link any such evidence.

The mainstream media coverage (Fox News, Exoskeleton Report) validates category relevance but does not constitute independent product performance testing.

12. Future Scenarios {#future-scenarios}

Our read — Bull case: Dephy successfully positions the Sidekick as the technically credible, specialist alternative in a consumer powered-footwear category that major brands (as evidenced by Nike's Project Amplify coverage) have validated as commercially real. Adaptive control expertise and ISO safety certification become durable differentiators. Dephy expands into occupational wellness, active-aging programs, or clinical adjacent markets, leveraging the same core technology platform. Brand recognition built through Exoskeleton Report and mainstream media coverage translates into consumer pull.

Our read — Base case: Dephy establishes a stable niche in the wellness-wearables market, building a loyal user base among early adopters interested in walking assistance. Growth is steady but measured, constrained by consumer education requirements (the product category is genuinely new to most buyers), price sensitivity, and the effort required to build retail distribution. The single-product portfolio creates concentration risk that a successful second product could address.

Our read — Bear case: Well-resourced consumer incumbents — footwear brands, consumer-electronics companies, or medical-device firms pivoting down-market — compress the price/performance envelope faster than a specialist firm can respond. The wellness (non-medical) classification, while reducing regulatory burden, may also limit reimbursement pathways and enterprise procurement channels that would otherwise support higher volume. Limited disclosed commercial traction makes it difficult for external stakeholders to assess momentum, potentially slowing partnership and investment conversations.

13. What to Watch {#what-to-watch}

• Second product announcement: Any expansion of the portfolio beyond the Sidekick would signal platform ambitions and broader market targeting.
• Clinical or biomechanical study publication: Peer-reviewed or white-paper evidence quantifying metabolic reduction or user outcomes would substantially strengthen commercial and credibility positioning.
• Distribution partnerships: Retail, employer-wellness, or health-system distribution agreements would be a leading indicator of commercial scaling.
• Pricing and availability disclosure: Currently not detailed publicly; any announcement clarifies the addressable consumer segment.
• ISO 13482 certification documentation: Public disclosure of the certification body and scope would validate the safety claim independently.
• Response to Nike/Project Amplify and other entrants: How Dephy communicates differentiation as major brands enter motor-assisted footwear will be a strategic signal.
• Funding or corporate disclosure: Any announced investment round, acqui-hire interest, or corporate partnership would materially update the risk and opportunity profile.
• Geographic market expansion: Any announcement of non-US market entry or regulatory approvals in additional jurisdictions.

14. Sources & Methodology {#sources-methodology}

Primary source: All factual claims in this report are grounded exclusively in data extracted from Dephy's own website (dephy.com), including the company description, About page text, and product listing for the Dephy Sidekick. All such information carries company-claim provenance and has not been independently verified by this report.

Third-party press: Three external sources are cited — Exoskeleton Report (exoskeletonreport.com), and two Fox News articles (foxnews.com, dated October 2025 and February 2026). These are cited as evidence of media coverage and category context, not as independent product-performance verification.

Inferences: Sections where reasoning extends beyond the literal source data are explicitly labeled "Our read:" to distinguish analyst inference from documented fact.

Gaps: Where information is absent from the source data, this report uses the formulation "Not yet disclosed:" followed by an invitation for the company to claim or correct, rather than asserting a negative as fact.

Rubric (applied uniformly to every company in this series):

1. Lead with verified strengths.
2. All negatives are gaps or labeled inferences, never unsourced assertions.
3. No figures, products, competitors, customers, or partnerships are invented.
4. Company self-description is always labeled as company-claim.
5. External sources are named and their role (validation vs. context) is explicit.
6. This methodology is identical for every report in the series, ensuring comparability.